Targeting PP2A in cancer: Combination therapies

Sahar Mazhar; Sarah E. Taylor; Jaya Sangodkar; Goutham Narla

doi:10.1016/j.bbamcr.2018.08.020

Targeting PP2A in cancer: Combination therapies

Sahar Mazhar
, Sarah E. Taylor
, Jaya Sangodkar
, Goutham Narla

Research output: Contribution to journal › Review article › peer-review

115 Scopus citations

Abstract

The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant transformation. Many groups have explored the therapeutic venue of combining PP2A reactivation with kinase inhibition to counteract the very changes in tumor suppressors and oncogenes that lead to cancer development. Conversely, inhibition of PP2A to complement chemotherapy and radiation-induced cancer cell death is also an area of active investigation. Here we review the studies that utilize PP2A targeted agents as combination therapy in cancer. A potential role for PP2A in tumor immunity is also highlighted.

Original language	English
Pages (from-to)	51-63
Number of pages	13
Journal	Biochimica et Biophysica Acta - Molecular Cell Research
Volume	1866
Issue number	1
DOIs	https://doi.org/10.1016/j.bbamcr.2018.08.020
State	Published - Jan 2019
Externally published	Yes

Keywords

Cell signaling
Protein phosphatases
Targeted therapies

Access to Document

10.1016/j.bbamcr.2018.08.020

Cite this

@article{fc64e0e11a3e4cb68e0d67a9f29fb039,

title = "Targeting PP2A in cancer: Combination therapies",

abstract = "The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant transformation. Many groups have explored the therapeutic venue of combining PP2A reactivation with kinase inhibition to counteract the very changes in tumor suppressors and oncogenes that lead to cancer development. Conversely, inhibition of PP2A to complement chemotherapy and radiation-induced cancer cell death is also an area of active investigation. Here we review the studies that utilize PP2A targeted agents as combination therapy in cancer. A potential role for PP2A in tumor immunity is also highlighted.",

keywords = "Cell signaling, Protein phosphatases, Targeted therapies",

author = "Sahar Mazhar and Taylor, \{Sarah E.\} and Jaya Sangodkar and Goutham Narla",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",

year = "2019",

month = jan,

doi = "10.1016/j.bbamcr.2018.08.020",

language = "English",

volume = "1866",

pages = "51--63",

journal = "Biochimica et Biophysica Acta - Molecular Cell Research",

issn = "0167-4889",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Targeting PP2A in cancer

T2 - Combination therapies

AU - Mazhar, Sahar

AU - Taylor, Sarah E.

AU - Sangodkar, Jaya

AU - Narla, Goutham

PY - 2019/1

Y1 - 2019/1

N2 - The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant transformation. Many groups have explored the therapeutic venue of combining PP2A reactivation with kinase inhibition to counteract the very changes in tumor suppressors and oncogenes that lead to cancer development. Conversely, inhibition of PP2A to complement chemotherapy and radiation-induced cancer cell death is also an area of active investigation. Here we review the studies that utilize PP2A targeted agents as combination therapy in cancer. A potential role for PP2A in tumor immunity is also highlighted.

AB - The serine/threonine phosphatase PP2A regulates a vast portion of the phosphoproteome including pathways involved in apoptosis, proliferation and DNA damage response and PP2A inactivation is a vital step in malignant transformation. Many groups have explored the therapeutic venue of combining PP2A reactivation with kinase inhibition to counteract the very changes in tumor suppressors and oncogenes that lead to cancer development. Conversely, inhibition of PP2A to complement chemotherapy and radiation-induced cancer cell death is also an area of active investigation. Here we review the studies that utilize PP2A targeted agents as combination therapy in cancer. A potential role for PP2A in tumor immunity is also highlighted.

KW - Cell signaling

KW - Protein phosphatases

KW - Targeted therapies

UR - https://www.scopus.com/pages/publications/85052927848

U2 - 10.1016/j.bbamcr.2018.08.020

DO - 10.1016/j.bbamcr.2018.08.020

M3 - Review article

C2 - 30401535

AN - SCOPUS:85052927848

SN - 0167-4889

VL - 1866

SP - 51

EP - 63

JO - Biochimica et Biophysica Acta - Molecular Cell Research

JF - Biochimica et Biophysica Acta - Molecular Cell Research

IS - 1

ER -

Targeting PP2A in cancer: Combination therapies

Abstract

Keywords

Access to Document

Fingerprint

Cite this